In this editorial, Dr. Cross states that vaccines and monoclonal antibodies directed at endotoxin are under development (by him and many others), but he does not endorse any one of the endotoxin-directed therapies discussed.
D
espite decades of research, it has been remarkably difficult to demonstrate the role of endotoxin in human disease. The dilemma, in part, stems from our inability to accurately measure endotoxin in the circulation and body fluids and make meaningful clinical correlations. The most commonly used method for detecting endotoxin is the Limulus amebocyte lysate (LAL) assay. Routinely used in the pharmaceutical industry to detect endotoxin contamination, this assay measures endotoxin's activity, not endotoxin itself. Endotoxins activate a cascade of procoagulant proteins found in the blood amebocytes of the horseshoe crab, Limulus polyphemus, resulting in coagulation that may be detected by clot formation, turbidity, or a chromogenic readout. Several factors may interfere with the sensitivity of the assay, including plasma proteins and lipids that bind the endotoxin. Consequently, heating and dilution of samples are required for more accurate measurement. The Limulus lysate also reacts with β-glucans found in fungi, but most commercial assay kits now include inhibitors of this reaction.
In this issue of Critical Care Medicine, Charbonney et al (1) used a different assay, the endotoxin activity (EA) assay, to evaluate the prevalence and kinetics of systemic endotoxemia in a cohort of 48 patients who were admitted to an ICU within 24 hours of sustaining severe trauma. While 46 of 48 patients had no endotoxemia at admission, endotoxemia developed in 75% of them, particularly after shock or early surgery, and endotoxemia predicted organ dysfunction. Since few patients had Gram-negative bacterial infections, the authors concluded that a loss of gastrointestinal barrier integrity was the most likely source of the circulating endotoxin.
The EA assay measures neither endotoxin nor its activity, but rather the ability of a putative lipopolysaccharide (LPS)/ monoclonal antibody (MAb) complex to prime the generation of reactive oxygen species (ROS) by the polymorphonuclear leukocytes (PMN) in the patient's blood. The blood sample is mixed with an IgM MAb, E5, that targets a broad range of LPS species. If LPS is present in the blood and binds to E5, the LPS/E5 immune complex activates complement, which interacts with neutrophil complement receptors to prime the cells; when opsonized zymosan is added, greater amounts of ROS are produced. The ROS are detected by adding luminol, which produces a chemiluminescent signal. The assay compares the chemiluminescent reading in the presence of the LPS/E5 complex with the chemiluminescence produced in control tubes that either lack the IgM antibody or contain maximal amounts of added LPS. The authors claim that this Food and Drug Administration-approved assay can be rapidly performed (< 30 vs 90-120 min for LAL) with less than 1 mL of whole blood and without need for cell purification or sample manipulation.
Several questions arise, however. E5 may detect the various LPSs that translocate into the circulation from the gastrointestinal tract with differing degrees of sensitivity. This may explain, in part, the unsuccessful clinical trial with E5 MAb for the treatment of sepsis (2) . In addition, preexisting antiendotoxin antibodies or endotoxin-binding proteins, such as LPS-binding protein and bactericidal/permeability-increasing protein (BPI), may compete with the E5 MAb for the LPS in the blood (3). Several confounding variables, such as possible endotoxin tolerance, soluble mediators (e.g., other immune complexes, cytokines/ chemokines, and circulating mitochondrial damage-associated molecular patterns present during trauma) (4), or sepsis itself, may also modify the PMN chemiluminescent response.
The detection of circulating endotoxin by LAL or EA alone cannot predict the impact of LPS on the septic course. Some LPSs that activate the LAL cannot stimulate human cells, while the E5 MAb may bind LPSs that are very weak agonists. Further, differences in a host's capacity to respond to LPS depend on many clinical factors that may limit the clinical utility of the LPS measurement.
Despite all the limitations of LPS measurement in biological fluids, reasonably consistent findings from several clinical studies, including the present one, suggest that high levels of plasma LPS are associated with excess risk of morbidity and mortality that is largely independent of the nature of the bacteria responsible for the septic episodes (3). During the last 25 years, not one of the clinical trials in which the downstream biologic effects of endotoxin (rather than the endotoxin itself) were targeted resulted in a licensed intervention. The authors importantly conclude that therapies directed at endotoxin should be reexamined. Given the likelihood that endotoxemia also may play a role in various "leaky gut" syndromes, such therapy may be useful in conditions beyond sepsis (5, 6) .
Still, there is a need to establish that specifically targeting LPS with therapeutic agents will reduce mortality in septic shock. Earlier studies documented that the level of anti-core endotoxin antibodies at the onset of sepsis correlated with outcome as did more recent studies with a commercial kit (7) (8) (9) . A clinical trial that administered polyclonal antibodies directed against a highly conserved epitope of endotoxin demonstrated impressive protective efficacy (10) . Although subsequent studies by other investigators failed to demonstrate similar protection, none insured that there were adequate antibody levels either before administration or during the trial (11) . Failure of clinical trials with antiendotoxin MAbs may be attributable to the inaccessibility of the lipid A target (2, 12) .
Interventions that should enhance the clearance of endotoxins from the circulation, such as vaccines and MAbs against Gram-negative bacteria (GNB), are in development. Clinical trials have examined whether polymyxin B hemoperfusion to remove circulating endotoxin may benefit patients with severe sepsis (13) . BPI protein, a neutrophilic cationic peptide, both neutralizes the biologic activity of LPS and is cidal for GNB. A clinical trial with a recombinant 22-kDa segment of BPI failed to reduce the mortality from meningococcal sepsis in children, but did reduce the number of complications in survivors (14) . With the dramatic increase in multidrug-resistant GNB, BPI is getting a "second look." Enthusiasm for these interventions should be tempered by knowledge that LPS neutralization might be harmful, as was suggested in two previous studies (2, 12) and by multiple preclinical studies showing that mice unable to respond to LPS are highly susceptible to lethal infection (15) . Given these considerations, investigators should consider monitoring endotoxemia at the onset and during studies of endotoxin-directed interventions, albeit with an awareness of the limitations.
